Follow the Data: Make decisions preclinically when comparing & combining cell therapies with new modalities1

Research Area: Checkpoint & combination therapy

Development Stage: Optimization

Goal: Identify differences and mechanism in combined cell therapies

[unex_ce_button id="content_10khx0ih9,column_content_611g46odk" button_text_color="#ffffff" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px" button_bg_color="#29acd8" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#29acd8" button_border_radius="0px" button_text_hover_color="#ffffff" button_text_spacing_hover="1px" button_bg_hover_color="#9cc9d8" button_border_hover_color="#9cc9d8" button_link="https://www.isoplexis.com/request-a-seminar" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Request a seminar
to follow our data >[/ce_button]

How our single-cell systems are making a difference

Solution: PSI revealed differences in control and new combination therapy, enhancing decision making

Finding: NKTR-214 elicited more polyfunctional subsets than IL-2, which correlates with results from complementary technologies

Follow the data

Polyfunctionality and Polyfunctional Strength are considerably increased in samples treated with ACT+NKTR-214 vs ACT+IL-2 (left). Sorted antigen-specific CD8+ T cells Thy1.+ from tumors and spleen D7 after ACT+NKTR-214 or ACT+IL-2 (3 mice/group) were stimulated and stained with anti-mouse CD8.

NKTR2-14 elicited more polyfunctional cell subsets in the adoptively transferred TCR-T cells in spleen and tumor compared to IL-2.1

[unex_ce_button id="content_om95el0ye,column_content_g32kkdowi" button_text_color="#424242" button_font="bold" button_font_size="18px" button_width="auto" button_alignment="right" button_text_spacing="1px " button_bg_color="#c9c9c9" button_padding="15px 30px 15px 30px" button_border_width="0px" button_border_color="#c9c9c9" button_border_radius="0px" button_text_hover_color="#424242" button_text_spacing_hover="1px" button_bg_hover_color="#e8e8e8" button_border_hover_color="#e8e8e8" button_link="https://isoplexis.com/wp-content/uploads/2019/02/IsoPlexis-AppHighlight-Bispecifics.pdf" button_link_type="url" button_link_target="_blank" has_container="" in_column="1"]Download application highlight
to learn more >[/ce_button]

IsoPlexis finds critical differences

Immuno-PET imaging using cys-diabody (cDb) targeting CD8 in vivo shows significant T cells expansion in spleen for ACT+NKTR-214-treated mice. Representative CD8 cys-diabody immuno-PET/CT images acquired on D5 after treatment with ACT+IL-2 or ACT+NKTR-214 (n=3/group). I.V. injection of Zr-89 labeled anti-CD8 cDb was performed 24h prior imaging of C57/BL6 mice.

NKTR-214 increases expression of genes associated with T cell cytotoxicity and memory. Clustering of chemokines and their receptors, showing a general trend of increased expression in the ACT+NKTR-214 group.1